| Revenue Growth | US revenue up 3% sequentially; International revenue down 9% in Q3. |
|---|---|
| Mgmt Confidence | Increasingly confident in 2027 return to growth as coding stabilizes. |
| Demand Visibility | Tracking $120 million impact from coding; patient funnel remains active. |
| Margin Trends | Gross margin 86%, up 20bps; adjusted operating margin 4.5% to 5.5%. |
| Op. Leverage | Project Horizon created $30 million annualized growth investment capacity. |
| Pricing Power | Inspire 5 carries higher gross margin than Inspire 4. |
| Vol vs Price | Growth driven by Inspire 5 adoption; volume impacted by coding changes. |
| Segment Growth | Inspire 5 now makes up the vast majority of procedures. |
| New Clients | Adding field roles in 40 high-potential growth markets to improve flow. |
| Capex & Debt | No debt; $453.1M cash; Capex $35M-$40M; $24.1M restructuring charges. |
| Regulatory | Category 1 CPT code approved for January 1, 2028 effective date. |
| Commentary | Shifting focus from coding stabilization to optimizing patient flow and cardiology referrals. |
| New Launches | Inspire 6 development targeting FDA submission in 2027. |
Growth
Q3 revenue $206.7M, down 7.9% YoY; US outperformed while International declined 9%.
Outlook
Guiding to low single-digit revenue growth for full year 2027.
Risks
Management pivoted to vague language regarding specific 2027 market growth rates and competitor impact.
The company's earnings call, NYSE: INSP, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Inspire Medical Systems, Inc.: key numbers
- Share price
- $59.12Close, Nov 16
- Market cap
- $1.71B
- Shares outstanding
- 28.97MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Inspire Medical Systems, Inc.
All →Inspire Medical Systems Q3 2026 Results: Net Loss of $24.4M
For the nine months ended September 30, 2026, Inspire Medical Systems reported a net loss of $35.4 million on revenue of $611.9 million, compared to a net profit of $9.3 million in the prior year period. The shift to a loss was driven by a decrease in revenue and a significant increase in selling, general, and administrative expenses.
- Key figure
- Net loss $24.4M
Inspire Medical Systems Financial Results
Inspire Medical Systems reported Q3 2026 revenue of $206.7 million, a 7.9% decrease year-over-year primarily due to U.S. coding and reimbursement challenges. Despite the revenue decline, the company achieved a positive adjusted diluted EPS of $0.14 and noted that the AMA approved new Category I CPT codes for its Inspire V system effective 2028.
- Term
- 3 months
“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic.”
Tim Herbert, Chairman and CEO of Inspire Medical Systems
“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy.”
Tim Herbert, Chairman and CEO of Inspire Medical Systems